NIH researchers angered by new ethics rules

Angered by new ethics rules, about four in 10 hands-on researchers at the NIH say they are either actively looking for new jobs or giving it serious thought. In a new survey, the scientists say the new rules--aimed at preventing conflicts of interest with drug developers--are too harsh and will make it difficult for the government agency to replace departing staffers. Conversely, about three out of four of NIH employees say the new rules will increase its credibility with the public. Researchers, though, clearly want to see a relaxation of the rules so that they aren't relegated to an ethical "monastery."

- here's the Washington Post's report on the NIH survey

Related Articles
Congress launches probe of NIH conflicts policies. Report
NIH researcher cited for misconduct. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.